This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

HealthCare Royalty Partners Commits Over $300 Million In New Investments In December And Over $425 Million In 2012

Stocks in this article: RPTP

STAMFORD, Conn., Jan. 3, 2013 /PRNewswire/ --  HealthCare Royalty Partners ("HC Royalty"), a global healthcare investment firm, today announced that it committed over $300 million in December 2012 across five investments. Total capital committed by the HC Royalty team in 2012 exceeded $425 million.

"2012 proved to be another robust year for deal activity in the royalty market. Our team evaluated several hundred investment opportunities and committed a significant amount of capital across eight investments. We believe the strength of this market is further validation that companies need access to a greater pool of capital to bring critical products to patients and move their pipelines forward," commented Todd Davis, Founding Managing Director at HC Royalty. He continued, "Our firm has been a significant financial resource for commercial stage and near commercial stage companies, as we offer a broad and flexible investment platform that delivers non-dilutive forms of capital."

Select 2012 product investments include:

LYRICA®: HC Royalty purchased a royalty interest in LYRICA® from an inventor. LYRICA® is one of Pfizer's premier drugs for the treatment of neuropathic pain with trailing twelve month sales exceeding $3.5 billion worldwide.  The firm believes this is one of the largest stand-alone inventor monetizations consummated.

Meningitec™, HibTITER®, NU100 and several other products: An $80 million structured financing was completed with privately-held Nuron Biotech. The financing included a $30 million equity investment and a $50 million Synthetic Royalty® agreement tied to future sales of Meningitec™, HibTITER® and the company's other products, including NU100. The capital is being used to support the commercialization and expansion of Meningitec™ (recently acquired from Pfizer), an established commercial vaccine for the prevention of invasive disease caused by Neisseria meningitidis serogroup C. It is also being used to fund the clinical development of the company's novel biologics and vaccines for infectious and neurodegenerative diseases. The financing is a structured deal that offers less dilutive growth capital for an emerging biopharmaceutical company.

PROCYSBI™: A $50 million loan agreement was completed with Raptor Pharmaceuticals (NASDAQ: RPTP) to help fund the commercialization of PROCYSBI™, the branded name of RP103 for the potential treatment of nephropathic cystinosis, and to advance the company's development programs. The loan which matures on December 31, 2019, bears interest at an annual fixed rate of 10.75% and a Synthetic Royalty® variable rate, tiered down, based on a percentage of future PROCYSBI sales. This financing represents another form of non-dilutive growth capital for a company on the verge of approval and launch of an important therapeutic product to treat an orphan indication.  

Eligard ® : HC Royalty acquired a royalty interest in Eligard® European sales from Medigene AG for $18 million. Eligard is a hormone compound for the treatment of advanced, hormone-dependent prostate cancer that is currently marketed by AstellasPharma Europe Ltd. This non-dilutive financing enabled Medigene to fund its pipeline including the company's lead drug candidate, Endotag for the treatment of pancreatic and breast cancer.

About HealthCare Royalty PartnersHealthCare Royalty Partners is a global healthcare investment firm focused on providing financing solutions to healthcare companies and royalty owners with interests in approved pharmaceutical and medical device products. The firm's senior investment team has participated in 45 royalty financings valued at over $2 billion over the past decade. For more information, visit www.healthcareroyalty.com/.   

Media Contact:          Kellie Walsh914-315-6072 kwalsh@kwmcommunications.com

SOURCE HealthCare Royalty Partners

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs